Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biogen Idec (NQ: BIIB )

265.17 +3.95 (+1.51%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 23, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Biogen Idec

< Previous 1 2 3 Next >
MarketBeat: Week in Review 10/3-10/7
The jobs report is fueling a sell-off to end the week with more volatility on tap for next week. Here are some of the most popular articles from this week. 
Via MarketBeat
Topics Economy Electric Vehicles
Exposures Electric Vehicles Interest Rates
3 Alzheimer Stocks to Buy as the Race for a Cure Heats Up
Here is a look at three names that buy-and-hold investors may want to consider as the race to find a cure for Alzheimer's disease accelerates 
Via MarketBeat
Exposures Product Safety
Biogen and Denali Therapeutics Announce Initiation of the Phase 3 LIGHTHOUSE Study in Parkinson’s Disease Associated with LRRK2 Pathogenic Mutations
From Denali Therapeutics Inc.
Via Globe NewsWire
Has The Controversy Around Falsified Alzheimer's Research Impacted The Path To Finding The Cure?
Finding the cure to Alzheimer’s has confounded researchers for decades. 
Via TheNewswire.com
Biogen Leads From the Top With Disability Inclusion
SOURCE: Biogen 
Via 3BL Media
Biogen Announced EMA Filing Acceptance of BIIB800, A Biosimilar Candidate Referencing RoACTEMRA® (tocilizumab)
From Biogen Inc.
Via Globe NewsWire
INVESTIGATION ALERT: Scott+Scott Attorneys at Law LLP Investigates Biogen Inc.’s Directors and Officers for Breach of Fiduciary Duties – BIIB
From Scott+Scott Attorneys at Law LLP
Via Business Wire
From Pause to Pride: A Mother's Journey
SOURCE: Biogen 
Via 3BL Media
Topics LGBTQ
Exposures Diversity
FDA Accepts Biogen’s New Drug Application and Grants Priority Review of Tofersen for a Rare, Genetic Form of ALS
From Biogen Inc.
Via Globe NewsWire
Biogen and Happify Health Collaborate to Support Multiple Sclerosis Patients on Digital Platform
From Happify Health
Via Business Wire
NASDAQ:BIIB Long Term Investor Alert: Investigation of Potential Wrongdoing at Biogen Inc.
San Diego, CA -- (SBWIRE) -- 06/10/2022 -- Certain directors of Biogen Inc. are under investigation over possible breaches of fiduciary duties. 
Via SBWire
Rising Cases Of Mental Health Disorders of Stress, Anxiety & Addiction Fueling Need for Central Nervous System Therapeutics
Palm Beach, FL – June 7, 2022 – FinancialNewsMedia.com News Commentary – The global Central Nervous System (CNS) treatments and its market revenues had been steadily growing pre-pandemic and are still... 
Via FinancialNewsMedia
Exposures COVID-19
Biogen and MedRhythms to Develop and Commercialize a Prescription Digital Therapeutic Targeting the Treatment of Gait Deficits in Multiple Sclerosis
From MedRhythms
Via Business Wire
Sage Therapeutics and Biogen Initiate Rolling Submission of New Drug Application (NDA) to U.S. Food and Drug Administration for Zuranolone for the Potential Treatment of Major Depressive Disorder (MDD)
From Sage Therapeutics, Inc.
Via Business Wire
Biogen Inc. (NASDAQ:BIIB) Investor Notice: Deadline in Lawsuit on April 8, 2022
San Diego, CA -- (SBWIRE) -- 03/28/2022 -- The Shareholders Foundation announced that a deadline is coming up on April 8, 2022 in the lawsuit filed for certain investors of Biogen Inc. (NASDAQ:BIIB). 
Via SBWire
NASDAQ:BIIB Investor Alert: Lawsuit Alleges Misleading Statements by Biogen Inc.
San Diego, CA -- (SBWIRE) -- 02/23/2022 -- An investor, who purchased NASDAQ:BIIB shares, filed a lawsuit against Biogen Inc over alleged Securities Laws violations. 
Via SBWire
BIIB Investor Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Biogen, Inc. Investors of Class Action and Encourages Investors to Contact the Firm
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
Psychedelic Drugs Market Growing as Prevalence of Mental Health Issues are Increasing Globally
Palm Beach, FL –– February 24, 2022 – FinancialNewsMedia.com News Commentary – The prevalence of mental health disorders has risen exponentially but the development of novel medications has not kept... 
Via FinancialNewsMedia
Exposures COVID-19
Biogen Update
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Biogen Class Action Reminder
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
BIIB Investor Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Biogen, Inc. Investors of Class Action and Encourages Investors to Contact the Firm
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
Shareholder Alert: Robbins LLP Reminds Investors Biogen, Inc. (BIIB) is Being Sued for Misleading Shareholders
From Robbins LLP
Via Business Wire
Biogen Shareholder Notice
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
BIOGEN ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Biogen, Inc. and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
Biogen Shareholder Alert
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
CORRECTING and REPLACING Shareholder Alert: Robbins LLP Informs Investors Biogen, Inc. (BIIB) is Being Sued for Misleading Shareholders
From Robbins LLP
Via Business Wire
Shareholder Alert: Robbins LLP Informs Investors Biogen, Inc. (BIIB) is Being Sued for Misleading Shareholders
From Robbins LLP
Via Business Wire
Biogen Deadline Alert
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Sage Therapeutics and Biogen Announce New Analyses from the LANDSCAPE Clinical Development Program of Zuranolone in MDD Presented at the American College of Neuropsychopharmacology (ACNP) Congress
From Sage Therapeutics, Inc.
Via Business Wire
Sage Therapeutics and Biogen Announce Positive, One-Year Zuranolone 50 mg Data in the Ongoing Open-Label SHORELINE Study in Patients with MDD
From Sage Therapeutics, Inc.
Via Business Wire
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.